Britannia Life Sciences Inc.
BLSIF
$0.06
$0.03100.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 46.90K | 81.20K | 122.70K | -- | 120.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.90K | 81.20K | 122.70K | -- | 120.20K |
| Cost of Revenue | 21.10K | 53.20K | 102.30K | -- | 75.80K |
| Gross Profit | 25.80K | 28.00K | 20.50K | -- | 44.40K |
| SG&A Expenses | 286.90K | 523.10K | 271.10K | -- | 477.20K |
| Depreciation & Amortization | 11.30K | 11.50K | 11.30K | -- | 10.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 319.30K | 587.90K | 384.60K | -- | 563.80K |
| Operating Income | -272.40K | -506.60K | -261.90K | -- | -443.60K |
| Income Before Tax | 8.98M | -298.60K | -499.40K | -- | -216.90K |
| Income Tax Expenses | 1.20M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.77M | -298.60K | -499.40K | -- | -216.90K |
| Earnings from Discontinued Operations | 925.30K | -- | -- | -- | 149.30K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -30.10K |
| Net Income | 8.70M | -298.60K | -499.40K | -- | -97.80K |
| EBIT | -272.40K | -506.60K | -261.90K | -- | -443.60K |
| EBITDA | -261.10K | -495.20K | -250.60K | -- | -432.80K |
| EPS Basic | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -- | 0.00 |
| EPS Diluted | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -- | 0.00 |
| Average Basic Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Average Diluted Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |